Literature summary for 3.4.21.76 extracted from

Hu, N.; Westra, J.; Huitema, M.G.; Bijl, M.; Brouwer, E.; Stegeman, C.A.; Heeringa, P.; Limburg, P.C.; Kallenberg, C.G.
Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils (2009), Arthritis Rheum., 60, 1548-1557.

Search for more literature for 3.4.21.76

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining
membrane	-	Homo sapiens	16020	-

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
neutrophil	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
PR3	-	Homo sapiens
proteinase 3	-	Homo sapiens

Expression

Organism	Comment	Expression
Homo sapiens	increased percentages of mPR3-expressing neutrophils in patients with ANCA-associated systemic vasculitis (median 67%, range 16-100%) and patients with systemic lupus erythematosus (median 80%, range 25-100%), but not in patients with rheumatoid arthritis (median 61%, range 0-100%). Correlation of CD177 expression with PR3 expression on primed neutrophils. After priming with tumor necrosis factor alpha, neutrophils remain negative for CD177 while PR3 expression is induced. Expression of PR3 on the neutrophil surface can be independent of CD177 expression. Among the patients with PR3 ANCA-associated vasculitis, patients treated with cyclophosphamide or prednisolone have higher percentages of CD177-expressing neutrophils than do patients who have not received these treatments	up

General Information

General Information	Comment	Organism
physiological function	neutrophil activation by PR3 antineutrophil cytoplasmic autoantibodies (ANCAs). CD177 may be a determinant of membrane expression of PR3 and, as such, influences the potential of neutrophils to be activated by PR3 ANCAs	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)